This year’s World Heart Day is centered around the theme of ‘Cardiovascular Health for Everyone,’ which raises awareness of the prevention, treatment and management of cardiovascular disease worldwide. At Jazz, we know that people living with sleep disorders, such as narcolepsy, face risks in developing some of these comorbidities, and we are committed to exploring solutions that can help effectively manage the impacts they face, including hypertension, cardiovascular disease, obesity and diabetes.

At Jazz, our purpose is to innovate to transform the lives of patients and their families. In the coming days, we are showcasing our ongoing commitment to the sleep community with our presence at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies.

We celebrated International Women’s Day and Women’s History Month with awareness-building events and engaging sessions with our Jazz Association of Women Supporters (JAWs) employee-led Affinity Forum, including a very special event for our employees featuring Brooke Baldwin, award-winning journalist and author of the book, Huddle: How Women Unlock Their Collective Power. After hearing from Brooke and having a rich dialogue, we closed out our Women’s History Month event with the announcement of distinguished recognition for two of our Jazz colleagues by the Healthcare Businesswomen’s Association (HBA) as 2022 honorees in the healthcare industry.

At Jazz, we push ourselves and other stakeholders to think holistically about patients’ health to minimize the risk of patient co-morbidities and address significant unmet needs. To learn more about the often-overlooked co-morbidities associated with narcolepsy and the progress Jazz has made to address them, Jazz's Dr. Todd Kirby spoke with sleep specialist Dr. Richard K. Bogan. 

At Jazz Pharmaceuticals, we’re committed to developing life-changing medicines for people affected by serious diseases for which current therapies are lacking. This begins with talking to those living with disease and reflecting their needs in our R&D priorities and throughout all stages of our drug development process as we pursue novel, meaningful medicines that advance patient care.

Bruce Cozadd, our Chief Executive Officer, looks back on Jazz’s major achievements of 2021 amid ongoing challenges of the pandemic, reflecting on the significant strides made for patient populations, and reinstating Jazz’s continued commitment to developing breakthrough therapeutics as we kick off 2022.